Antibodies for the treatment of Clostridium difficile-associated infection and disease

US8986697B2 · kind B2 · utility

Assignee

• Progenics Pharmaceuticals, Inc. · US

Inventors

• Dangshe Ma · Millwood, US
• Kirsten Nagashima · Valhalla, US
• Brian Kennedy · Kirkland, CA
• Gerald P. Donovan · Kittery, US
• Yun Kang · Livingston, US
• William Olson · Ossining, US
• Shankar Kumar · Pleasanton, US
• Naoya Tsurushita · Palo Alto, US
• Andre Marozsan · Boston, US
• Albert Cupo · Stamford, US

Key dates

• Filing date: Apr 15, 2011
• Grant date: Mar 24, 2015
• Expiry date: May 18, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are reagents, compositions, and therapies with which to treat Clostridium difficile infection and related disease conditions and pathologies, such as Clostridium difficile-associated diarrhea, resulting from infection by Clostridium difficile bacteria and the enterotoxins produced by these bacteria. In particular, antibodies or antigen-binding fragments thereof that bind specifically to toxin A and/or toxin B of C difficile and neutralize the activities of these toxins; compositions comprising such antibodies; and methods of using the antibodies and the compositions are provided.